Biopharma News

Aug 31, 2017
By BioPharm International Editors
MilliporeSigma announced a collaboration with Angiex, a biotechnology start-up, to support the development of Angiex’s lead oncology antibody drug candidate to clinical use.
Aug 31, 2017
By BioPharm International Editors
Hospira, a Pfizer company, is voluntarily recalling one lot of vancomycin hydrochloride for injection, USP, 750 mg/vial because of glass within a single vial.
Aug 30, 2017
By BioPharm International Editors
Genentech’s Actemra (tocilizumab), a rheumatoid arthritis drug, has been approved for a new indication, treating CAR T cell-induced cytokine release syndrome (CRS), a side effect of CAR T cell therapy.
Aug 30, 2017
By BioPharm International Editors
FDA issued a Refusal to File letter to Acorda Therapeutics, citing insufficiently complete information in the company’s new drug application for its investigational Parkinson’s disease drug.
Aug 29, 2017
By BioPharm International Editors
AstraZeneca and Takeda will partner to develop and commercialize MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).
Aug 29, 2017
By BioPharm International Editors
Gilead will gain a robust pipeline of cell therapy products, with one lead candidate, a CAR T therapy, anticipated to gain FDA approval in the fourth quarter.
Aug 28, 2017
By BioPharm International Editors
The acquisition of Protein Sciences, a vaccines biotechnology company, strengthens Sanofi’s influenza vaccines portfolio.
Aug 28, 2017
By BioPharm International Editors
Genentech gets priority review for its application seeking a new indication for its anti-cancer drug, Gazyva (obinutuzumab), in treating follicular lymphoma.
Aug 25, 2017
By BioPharm International Editors
The generic pharmaceuticals firm has sold its Baddi, India formulations manufacturing facility following a recent fire at its joint-venture plant in Algeria.
Aug 24, 2017
By BioPharm International Editors
Xellia Pharmaceuticals completed the expansion of its laboratory services building at its Budapest manufacturing site.
native1_300x100
lorem ipsum